Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

1. A meta analysis of TCM kidney-nourishing formula in comparison with donepezil in the treatment of Alzheimer's disease

A meta analysis of TCM kidney-nourishing formula in comparison with donepezil in the treatment of Alzheimer's disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

2. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Discover Portal Discover Portal Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Published on 11 December 2015 doi: This follow up study (...) examined whether the drugs donepezil or memantine affected the chance that people with Alzheimer’s disease could continue to live in the community, rather than move permanently to a nursing home. One or both of the drugs was taken for a year and then participants could have any treatment thereafter. The study found that stopping donepezil doubled the risk of going into a nursing home up to a year afterwards, compared with continuing to take donepezil. However, there was no difference over

2018 NIHR Dissemination Centre

3. Donepezil

Donepezil Top results for donepezil - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for donepezil The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

4. Donepezil for dementia due to Alzheimer's disease. (PubMed)

Donepezil for dementia due to Alzheimer's disease. Alzheimer's disease is the most common cause of dementia in older people. One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by blocking the action of the enzyme responsible for the breakdown of the neurotransmitter acetylcholine. This can be done by a group of drugs known as cholinesterase inhibitors. Donepezil is a cholinesterase inhibitor.This review is an updated version (...) of a review first published in 1998.To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer's disease; to compare the efficacy and safety of different doses of donepezil; and to assess the effect of donepezil on healthcare resource use and costs.We searched Cochrane Dementia and Cognitive Improvement's Specialized Register, MEDLINE, Embase, PsycINFO and a number of other sources on 20 May 2017 to ensure that the search was as comprehensive

2018 Cochrane

5. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Discover Portal Discover Portal Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Published on 11 December 2015 doi: This follow up study (...) examined whether the drugs donepezil or memantine affected the chance that people with Alzheimer’s disease could continue to live in the community, rather than move permanently to a nursing home. One or both of the drugs was taken for a year and then participants could have any treatment thereafter. The study found that stopping donepezil doubled the risk of going into a nursing home up to a year afterwards, compared with continuing to take donepezil. However, there was no difference over

2018 NIHR Dissemination Centre

6. Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules

Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules U.S. Department of Health and Human Services Search FDA Submit search Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Namzaric (memantine hydrochloride extended-release/donepezil hydrochloride) Capsules Company: Forest Laboratories, Inc. Application No.: 206439 Approval Date: 12/23/2014

2014 FDA - Drug Approval Package

7. Acrescent (memantine hydrochloride / donepezil hydrochloride)

Acrescent (memantine hydrochloride / donepezil hydrochloride) 18 October 2012 EMA/111381/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Acrescent International non-proprietary name: memantine hydrochloride / donepezil hydrochloride Procedure No. EMEA/H/C/002424 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European (...) Assessment report Page 2/63 IMP Investigational medicinal product IMS-IPD IMS-Prescribing Insights Database ip intraperitoneal IT Italy ITT Intent to treat LC/MS/MS Liquid chromatography with tandem mass spectrometric detection LOCF Last observation carried forward Log Kow octanol-water partition coefficient MADRS Montgomery and åsberg depression rating scale MCID Minimal clinically important difference MDS Minimum data set MEM/DPZ Memantine/ donepezil MMSE Mini mental state examination MoA Mechanism

2013 European Medicines Agency - EPARs

8. Balaxur (memantine hydrochloride / donepezil hydrochloride)

Balaxur (memantine hydrochloride / donepezil hydrochloride) 18 October 2012 EMA/817438/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Balaxur International non-proprietary name: memantine hydrochloride / donepezil hydrochloride Procedure No. EMEA/H/C/002708 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European (...) Assessment report Page 2/63 IMP Investigational medicinal product IMS-IPD IMS-Prescribing Insights Database ip intraperitoneal IT Italy ITT Intent to treat LC/MS/MS Liquid chromatography with tandem mass spectrometric detection LOCF Last observation carried forward Log Kow octanol-water partition coefficient MADRS Montgomery and åsberg depression rating scale MCID Minimal clinically important difference MDS Minimum data set MEM/DPZ Memantine/ donepezil MMSE Mini mental state examination MoA Mechanism

2013 European Medicines Agency - EPARs

9. Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine

Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor (...) name or password? You are here Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Article Text Therapeutics Randomised controlled trial Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Pierre N Tariot Statistics

2013 Evidence-Based Medicine (Requires free registration)

10. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Hartz S, Getsios D, Tao S, Blume S, Maclaine G Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of donepezil, for the treatment of Alzheimer’s disease, versus memantine or no treatment, in Germany. The authors concluded that donepezil was highly cost-effective. The methods were appropriate

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

11. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial (PubMed)

Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-blind, placebo-controlled exploratory phase 2 trial.One-hundred forty patients with DLB, recruited from 48 specialty centers in Japan, were randomly assigned to receive placebo or 3, 5, or 10 mg of donepezil hydrochloride daily (...) = 0.004) at 10 mg/day. The safety results were consistent with the known profile of donepezil and similar among groups.Donepezil at 5 and 10mg/day produces significant cognitive, behavioral, and global improvements that last at least 12 weeks in DLB patients, reducing caregiver burden at the highest dose. Donepezil is safe and well tolerated.Copyright © 2012 American Neurological Association.

Full Text available with Trip Pro

2012 EvidenceUpdates

12. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. (PubMed)

Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. 22711111 2012 08 20 2013 04 17 1539-3704 156 12 2012 Jun 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. JC6-10 10.7326/0003-4819-156-12-201206190-02010 Burke David D St. Vincent's Health Network, Sydney, New South Wales, Australia. eng Comment Journal Article United States Ann Intern Med

2012 Annals of Internal Medicine

13. Donepezil and memantine for moderate-to-severe Alzheimer's disease. (PubMed)

Donepezil and memantine for moderate-to-severe Alzheimer's disease. Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini (...) -Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment

Full Text available with Trip Pro

2012 NEJM

14. Significant Dose Differences in Donepezil Purchased From the United States and Canada (PubMed)

Significant Dose Differences in Donepezil Purchased From the United States and Canada 21844564 2011 10 06 2018 12 01 1539-3704 155 4 2011 Aug 16 Annals of internal medicine Ann. Intern. Med. Significant dose differences in donepezil purchased from the United States and Canada. 279-80 10.7326/0003-4819-155-4-201108160-00026 Wang Chong-Zhi CZ Du Guang-Jian GJ Zhen Zhong Z Calway Tyler T Yuan Chun-Su CS eng K01 AT005362 AT NCCIH NIH HHS United States AT004418 AT NCCIH NIH HHS United States P01 (...) AT004418 AT NCCIH NIH HHS United States P01 AT004418-04 AT NCCIH NIH HHS United States AT005362 AT NCCIH NIH HHS United States K01 AT005362-02 AT NCCIH NIH HHS United States Letter Research Support, N.I.H., Extramural United States Ann Intern Med 0372351 0003-4819 0 Cholinesterase Inhibitors 0 Indans 0 Piperidines 0 Prescription Drugs 0 Tablets 8SSC91326P Donepezil AIM IM Alzheimer Disease drug therapy Canada Cholinesterase Inhibitors administration & dosage economics Donepezil Humans Indans

Full Text available with Trip Pro

2011 Annals of Internal Medicine

15. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. (PubMed)

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. The goal of this study was to determine if memory would be improved by donepezil as compared to placebo in a multicenter, double-blind, randomized clinical trial (RCT).Donepezil 10 mg daily was compared to placebo to treat memory impairment. Eligibility criteria included the following: age 18-59 years, clinically definite multiple sclerosis (MS), and performance ≤ ½ SD below published norms (...) on the Rey Auditory Verbal Learning Test (RAVLT). Neuropsychological assessments were performed at baseline and 24 weeks. Primary outcomes were change on the Selective Reminding Test (SRT) of verbal memory and the participant's impression of memory change. Secondary outcomes included changes on other neuropsychological tests and the evaluating clinician's impression of memory change.A total of 120 participants were enrolled and randomized to either donepezil or placebo. No significant treatment effects

Full Text available with Trip Pro

2011 EvidenceUpdates

16. Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy (PubMed)

Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy Cognitive impairment in late-life depression is a core feature of the illness.To test whether donepezil hydrochloride and antidepressant therapy is superior to placebo and antidepressant therapy in improving cognitive performance and instrumental activities of daily living and in reducing recurrences (...) of depression over 2 years of maintenance treatment.Randomized, double-blind, placebo-controlled maintenance trial.University clinic.One hundred thirty older adults aged 65 years and older with recently remitted major depression.Random assignment to maintenance antidepressant pharmacotherapy and donepezil or to maintenance antidepressant pharmacotherapy and placebo.Global neuropsychological performance, cognitive instrumental activities of daily living, and recurrent depression.Donepezil and antidepressant

Full Text available with Trip Pro

2011 EvidenceUpdates

17. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Overview | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 20 June 2018 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (NG97) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in June 2018 in NICE’s guideline on dementia (NG97

2011 National Institute for Health and Clinical Excellence - Technology Appraisals

18. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size (PubMed)

Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size We sought to assess the efficacy and safety of donepezil in patients with vascular dementia (VaD) fulfilling National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria.This international, multicenter, 24-week trial was conducted from March 2003 to August 2005. Patients (N=974; mean age (...) , 73.0 years) with probable or possible VaD were randomized 2:1 to receive donepezil 5 mg/d or placebo. Coprimary outcome measures were scores on the Vascular-Alzheimer Disease Assessment Scale-Cognitive Subscale and Clinician's Interview-Based Impression of Change, plus carer interview. Analyses were performed for the intent-to-treat population with the last-observation-carried-forward method.Compared with placebo, donepezil-treated patients showed significant improvement from baseline to end point

Full Text available with Trip Pro

2010 EvidenceUpdates

19. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model

Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Kasuya M, Meguro K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared donepezil therapy for patients with a clinical dementia rating (CDR) of 1.0; of 0.5; or of 0.5 who were identified as converters to 1.0. The authors concluded that the annual chance of decline had to be reduced from 15% to 12%, through the detection of CRD 0.5 converters, to produce

2010 NHS Economic Evaluation Database.

20. Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil

Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) are taking donepezil Article Text Therapeutics Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil Statistics from Altmetric.com Question Question Does atorvastatin improve cognition in patients with mild to moderate Alzheimer's disease (AD)? Patients 640 adults (age 50–90 years) patients with mild to moderate probable AD with a mini-mental state examination (MMSE) score 13–25, and taking donepezil 10 mg daily for ≥3 months

2010 Evidence-Based Mental Health